C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:10Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy